Deutsche Bank Upgrades Sepracor to 'Buy'

Analyst David Steinberg says the company's insomnia drug Estorra is critical to its profit outlook over the next several years

Sepracor (SEPR ) says it received an "approvable" letter from the FDA for its New Drug Application for Estorra brand eszopiclone. Deutsche Bank upgraded the stock to buy from hold.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.